Lexeo Therapeutics' (NASDAQ:LXEO - Get Free Report) lock-up period is set to end on Wednesday, May 1st. Lexeo Therapeutics had issued 9,090,910 shares in its public offering on November 3rd. The total size of the offering was $100,000,010 based on an initial share price of $11.00. After the expiration of the company's lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company will be lifted.
Lexeo Therapeutics Price Performance
Shares of NASDAQ:LXEO traded up $0.36 during trading on Wednesday, hitting $12.50. 99,355 shares of the stock traded hands, compared to its average volume of 103,588. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.21 and a quick ratio of 7.21. The business's fifty day simple moving average is $14.48. Lexeo Therapeutics has a 52-week low of $9.00 and a 52-week high of $22.33.
Lexeo Therapeutics (NASDAQ:LXEO - Get Free Report) last posted its earnings results on Monday, March 11th. The company reported ($0.86) earnings per share for the quarter, missing the consensus estimate of ($0.71) by ($0.15). Equities research analysts forecast that Lexeo Therapeutics will post -3.03 EPS for the current year.
Institutional Investors Weigh In On Lexeo Therapeutics
A number of institutional investors have recently added to or reduced their stakes in LXEO. Eventide Asset Management LLC acquired a new stake in Lexeo Therapeutics in the 4th quarter valued at $40,298,000. Omega Fund Management LLC acquired a new stake in Lexeo Therapeutics during the 4th quarter worth $28,955,000. Finally, Blackstone Inc. acquired a new stake in Lexeo Therapeutics during the 4th quarter worth $9,342,000. Institutional investors and hedge funds own 60.67% of the company's stock.
About Lexeo Therapeutics
(
Get Free Report)
Lexeo Therapeutics, Inc operates as a clinical-stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of HCM caused by TNNI3 mutations.
See Also
Before you consider Lexeo Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lexeo Therapeutics wasn't on the list.
While Lexeo Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
